60 | EYEWORLD DAILY NEWS | JULY 23, 2021
Patients should have insured access to the necessary treatment
for MGD, and doctors should receive fair reimbursement for
that treatment.
Today, we don't have this. Which is why only 5% of patients
get a heat and expression treatment
1
, when 86% may need it.
2
We say that's not right for anyone. Sight Sciences and the
TearCare® System are boldly stepping forward to fight for
equitable care. Learn more about our vision to remove the
barriers to MGD care.
Come by our booth #1001
THIS IS
YOUR SIGN
TO FIGHT FOR
EQUITABLE
MGD CARE
Shawn O'Neil
Chief Commercial O cer
© 2022 Sight Sciences, Inc. 4/22 TC-2331-US.v1
1. Market Scope 2021 Ocular Surface Disease Survey
2. Lemp, MA., et al. Cornea. 2012;31(5),472-478.
Indications for Use: The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease
due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for contraindications, warnings, precautions
and adverse events.
